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Phe Relative Strength of C-Reactive Protein and
ipid Levels as Determinants of Ischemic Stroke
ompared With Coronary Heart Disease in Women
rendan M. Everett, MD,*†‡§ Tobias Kurth, MD, SCD,*¶ Julie E. Buring, SCD,*†§
aul M Ridker, MD, MPH, FACC*†§
oston, Massachusetts
OBJECTIVES We sought to determine the relative strength of high-sensitivity C-reactive protein (hs-CRP)
and lipid levels as markers for future ischemic stroke compared with coronary heart disease
(CHD) in women.
BACKGROUND Although hs-CRP and lipid levels are established risk determinants for vascular disease, the
relative strength of these biomarkers for ischemic stroke compared with CHD is uncertain.
METHODS Among 15,632 initially healthy women who were followed for a 10-year period, we compared
hs-CRP, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), non–high-
density lipoprotein cholesterol (non-HDL-C), high-density lipoprotein cholesterol (HDL-
C), apolipoproteins A-I and B100, and lipid ratios as determinants of ischemic stroke
compared with CHD.
RESULTS After adjustment for age, smoking status, blood pressure, diabetes, and obesity, the hazard
ratios (HRs) and 95% confidence intervals (CIs) for the third versus the first tertile for future
ischemic stroke compared with CHD were, respectively, 1.91 (95% CI 1.13 to 3.21) and 2.26
(95% CI 1.64 to 3.12) for TC, 1.29 (95% CI 0.83 to 2.02) and 2.09 (95% CI 1.53 to 2.85)
for LDL-C, 0.57 (95% CI 0.36 to 0.92) and 0.38 (95% CI 0.27 to 0.52) for HDL-C, 1.72
(95% CI 1.03 to 2.86) and 2.93 (95% CI 2.04 to 4.21) for non–HDL-C, and 2.76 (95% CI
1.51 to 5.05) and 1.66 (95% CI 1.17 to 2.34) for hs-CRP. Of the lipid ratios, that of TC to
HDL-C had the largest HR for both future ischemic stroke and CHD (HR 1.95 [95% CI
1.16 to 3.26] and 4.20 [95% CI 2.79 to 6.32], respectively).
CONCLUSIONS In this large prospective cohort of initially healthy women, lipid levels are significant risk
determinants for ischemic stroke, but with a magnitude of effect smaller than that observed
for CHD. High-sensitiviy CRP associates more closely with ischemic stroke than with CHD.
Concomitant evaluation of lipid levels and hs-CRP may improve risk assessment for stroke
as well as CHD. (The Women’s Health Study; http://www.clinicaltrials.gov/ct/show/
NCT00000479/; NCT00000479) (J Am Coll Cardiol 2006;48:2235–42) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.030American College of Cardiology Foundation
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clthough hyperlipidemia and inflammation play major roles
n atherothrombosis, there has been controversy regarding
he relative contribution of these processes to ischemic
troke compared with coronary heart disease (CHD). For
xample, although both lipid levels and high-sensitivity
-reactive protein (hs-CRP) predict CHD (1–8), several
tudies have not found lipid levels to predict incident stroke
9–15). In contrast, some earlier studies of hs-CRP and
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eld by the Brigham and Women’s Hospital that pertain to the use of inflammatory
iomarkers in cardiovascular disease.w
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ccepted September 11, 2006.ther inflammatory biomarkers have suggested that these
arkers are closely associated with future stroke, although
ata are somewhat limited in women (2,16–19). Although
ethodologic issues, such as considering only fatal stroke
12), combining hemorrhagic and ischemic stroke as a single
nd point (11), or being restricted to somewhat limited
ample sizes (9,10), may have contributed to the lack of a
elationship between cholesterol and stroke described by
any investigators, it is also possible that inflammation and
yperlipidemia contribute differentially to clinical events in
he cerebral and coronary vascular beds.
To address these issues, we analyzed a full lipid panel and
s-CRP in a large-scale cohort of women with the specific
im of evaluating the magnitude of risk for each biomarker
or ischemic stroke compared with CHD.
ETHODS
he Women’s Health Study (WHS) is a randomized
ouble-blind placebo-controlled 2  2 factorial design trial
f aspirin and vitamin E in the primary prevention of
ardiovascular disease and cancer among initially healthy
omen aged 45 years or older. Participants were enrolled
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Lipids, CRP, Stroke, and CHD in Women December 5, 2006:2235–42etween November 1992 and July 1995 and were followed
rospectively for all cardiovascular events, including nonfa-
al myocardial infarction, nonfatal stroke, coronary revascu-
arization procedures, and cardiovascular-related death. All
articipants in the WHS provided written informed con-
ent, and the study protocol was approved by the institu-
ional review board of the Brigham and Women’s Hospital
Boston, Massachusetts).
The methods of end point validation have been described
lsewhere in detail (20). Briefly, an end points committee
omposed of physicians reviewed the medical records of all
omen who were reported to have suffered a cardiovascular
vent. Coronary heart disease was defined as a composite of
onfirmed fatal or nonfatal myocardial infarction, death
rom coronary artery disease, and coronary revascularization.
myocardial infarction was confirmed if symptoms met
orld Health Organization criteria and it was accompanied
y diagnostic electrocardiographic changes or abnormal
levations in serum cardiac enzymes. Stroke was defined as
new focal neurologic deficit of sudden onset and vascular
rigin that persisted for more than 24 h. Clinical informa-
ion and radiographic brain scans were used to distinguish
emorrhagic from ischemic strokes. The interobserver
greement in the classification of stroke into hemorrhagic
nd ischemic subtypes in the WHS has been shown to be
xcellent (21).
Among WHS participants, 28,345 women provided
lood samples that were stored in liquid nitrogen until the
ime of analysis. These samples underwent lipid analysis and
valuation for hs-CRP in a core laboratory certified by the
ational Heart, Lung, and Blood Institute/Centers for
isease Control and Prevention Lipid Standardization
rogram. Levels of total cholesterol and high-density li-
oprotein cholesterol (HDL-C) were measured enzymati-
ally on a Hitachi 911 autoanalyzer (Roche Diagnostics,
asel, Switzerland), and low-density lipoprotein cholesterol
LDL-C) was determined directly (Genzyme, Cambridge,
assachusetts). Levels of apolipoproteins B100 and A-I
ere measured by an immunoturbidometric technique on
he Hitachi 911 analyzer (22). High-sensivity CRP was
easured using a validated immunoturbidometric method
Denka Seiken, Tokyo, Japan) (23). Of the samples received
Abbreviations and Acronyms
ARIC  Atherosclerosis Risk in Communities
CHD  coronary heart disease
CI  confidence interval
HDL-C  high-density lipoprotein cholesterol
HR  hazard ratio
hs-CRP  high-sensitivity C-reactive protein
LDL-C  low-density lipoprotein cholesterol
LR  likelihood ratio
TC  total cholesterol
WHS  Women’s Health Studyy the core laboratory, 27,748 (98%) underwent successful Hvaluation for each biomarker. Non–HDL-C was calculated
y subtracting HDL-C from total cholesterol (TC).
We restricted our analysis to women who were not using
ormone therapy at the time of lipid analysis (n  15,632),
ecause of guidelines issued by the U.S. Department of
ealth and Human Services (24) and because hormone
herapy is known to alter lipid and inflammatory biomarker
evels (25–27).
tatistical analysis. Population distributions were com-
uted for each marker, and Spearman correlation coeffi-
ients were used to test for relationships between each of the
ipid subfractions and hs-CRP. Baseline levels of each blood
arameter were divided into increasing tertiles. We used
ox proportional hazards models to calculate hazard ratios
HRs) and 95% confidence intervals (CIs) for future CHD
nd ischemic stroke by comparing the second and third
ertiles using the lowest tertile as the reference group. The
Rs were adjusted on an a priori basis for age, randomized
reatment assignment, Framingham blood pressure cate-
ory, body mass index (BMI), diabetes, and smoking status.
or any study participant who suffered both a CHD event
nd an ischemic stroke, only the first event was used in this
nalysis. Tests for trends across tertiles of each biomarker
ere addressed by entering a single ordinal term based on
he median value for that biomarker within each tertile.
ata analysis was conducted using SAS statistical software
ersion 9.1 (SAS Institute, Cary, North Carolina).
ESULTS
ean (SD) age at baseline for the 15,632 initially healthy
omen followed for this portion of the study was 53.5 (7.7)
ears, and the mean (SD) BMI was 26.3 (5.3) kg/m2. As
reviously reported (28), TC, LDL-C, non–HDL-C, and
polipoprotein B100 were all highly correlated with one
nother (r values ranged from 0.76 to 0.93; all significant to
 0.0001). The levels of HDL-C and apolipoprotein A-I
ere highly correlated with one another (r  0.80) but only
eakly correlated with the other lipid variables. In contrast,
he correlation between hs-CRP and the lipid variables was
eaker, ranging from r  0.33 (p  0.0001) with
DL-C to r  0.15 (p  0.0001) with LDL-C.
Over the follow-up period of 10 years, 468 subjects
uffered a first cardiovascular event (132 ischemic stroke,
36 CHD). As expected, there were significant differences
n mean age, mean BMI, history of hypertension, diabetes,
nd smoking status across the groups of women who did not
uffer a cardiovascular event and those who reached either
ardiovascular end point (Table 1). The median levels of the
ipid values, their ratios, and hs-CRP in each of the 3 groups
f women are also shown in Table 1. Women with incident
HD were more likely to have a parental history of
yocardial infarction before the age of 60 than women with
schemic stroke and had slightly lower HDL-C and apoli-
oprotein A-I levels. Perhaps because of these differences in
DL-C and apolipoprotein A-I, lipid ratios were slightly
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omen with incident stroke.
The fully adjusted HRs for developing future ischemic
troke and coronary heart disease for each of the single lipid
ariables and hs-CRP are presented in Table 2. After adjust-
ent for age (years), blood pressure (Framingham categories),
iabetes, BMI (kg/m2), current smoking status, and random-
zed treatment assignment, increasing tertiles of TC, non-
DL-C, HDL-C, and hs-CRP were all associated with
uture ischemic stroke (ptrend  0.02, 0.03, 0.02, and 0.003,
espectively). Specifically, the HR of future stroke for those
omen in the highest compared with the lowest tertile was
.91 (95% CI 1.13 to 3.21) for TC, 1.72 (95% CI 1.03 to 2.86)
or non–HDL-C, 0.57 (95% CI 0.36 to 0.92) for HDL-C,
nd 2.76 (95% CI 1.51 to 5.05) for hs-CRP. Although the
ssociations between increasing tertiles of LDL-C and apoli-
oproteins B100 and A-I were not statistically significant, the
stimates of the HRs were in the expected direction (HR 
.29, 95% CI 0.83 to 2.02 for LDL-C; HR  1.47, 95% CI
.88 to 2.44 for apolipoprotein B100; and HR 0.72, 95% CI
.47 to 1.11 for apolipoprotein A-I), consistent with the
irection of effect for other highly correlated lipid variables.
mong the significant risk determinants for future ischemic
able 1. Baseline Clinical Characteristics of the Study Participan
Characteristic
Women Witho
Incident CHD
Ischemic Strok
(n  15,164)
ean age in yrs (SD) 53.3 (7.5)
ean body mass index (SD)† 26.2 (5.3)
istory of hypertension (%) 23.9
istory of diabetes (%) 2.9
arental history of myocardial infarction
before age 60 (%)
12.8
istory of high cholesterol (%) 26.4
moking status‡
Former 35.5
Current 11.8
Never 52.6
edian cholesterol, mg/dl (IQR)
Total cholesterol 205.0 (54.0)
LDL 123.2 (44.7)
HDL 49.3 (17.6)
Non-HDL 154.2 (54.4)
edian apolipoprotein, mg/dl (IQR)
A-I 140.6 (28.4)
B100 98.9 (37.8)
edian high-sensitivity CRP, mg/l (IQR) 1.48 (2.80)
edian lipid ratios (IQR)
Total cholesterol to HDL-C 4.12 (1.77)
LDL to HDL cholesterol 2.52 (1.33)
Apolipoprotein B100 to A-I 0.71 (0.32)
Apolipoprotein B100 to HDL-C 2.02 (1.26)
The p values are for women with incident ischemic stroke versus those with incide
-sample rank sum tests for variables not assumed to be normally distributed, and c
ivided by the square of the height in meters. ‡Because of rounding, not all percentage
HD or ischemic stroke were all  0.0002 except BMI (p  0.03), parental history
values for women with incident CHD versus those without incident CHD or isch
BMI  body mass index; CHD  coronary heart disease; CRP  C-reactive pro
ow-density lipoprotein-cholesterol.troke, the magnitude of association as measured by the cikelihood ratio (LR) chi-square was 213.7 for hs-CRP, 208.0
or TC, 207.3 for HDL-C, and 206.1 for non–HDL-C.
The fully adjusted HRs for lipid ratios as determinants of
schemic stroke are summarized in Table 3. The ratios of
C to HDL-C, LDL-C to HDL-C, and apolipoprotein
100 to HDL-C all associated with future ischemic stroke
ptrend  0.004, 0.01, and 0.03, respectively), and the ratio
f apolipoprotein B100 to A-I was of borderline significance
ptrend  0.08). Specifically, the HRs of future ischemic
troke for those in the highest compared with the lowest
ertile were 1.95 (95% CI 1.16 to 3.26) for the TC to
DL-C ratio, 1.77 (95% CI 1.08 to 2.90) for the LDL-C
o HDL-C ratio, 1.42 (95% CI 0.88 to 2.30) for the ratio of
polipoproteins B100 to A-I, and 1.62 (95% CI 0.98 to
.68) for the apolipoprotein B100 to HDL-C ratio. The
atio of TC to HDL-C had an LR chi-square of 210.1,
hich was similar to that of many of the single lipid
easures but smaller than for hs-CRP (LR chi-square 
13.7).
As anticipated, all of the measured lipid levels and
s-CRP were associated with future CHD (Table 2). After
djustment, the magnitude of association appeared to be
reatest for HDL-C, with an HR of CHD for the highest
Women With
Incident
Ischemic Stroke
(n  132)
Women With
Incident
CHD
(n  336) p Value*
61.3 (9.1) 58.9 (8.1) 0.006
27.3 (5.7) 28.3 (5.8) 0.09
55.3 45.8 0.07
18.2 19.9 0.67
9.8 20.1 0.01
42.4 48.2 0.26
33.1 33.6
23.9 25.6 0.89
43.1 40.8
228.5 (55.5) 227.0 (53.5) 0.90
139.0 (48.3) 141.2 (42.4) 0.38
45.2 (16.4) 41.8 (14.5) 0.03
175.3 (52.6) 181.4 (50.1) 0.40
135.7 (30.2) 131.7 (25.9) 0.02
117.1 (45.6) 122.0 (37.3) 0.24
2.85 (5.60) 3.14 (4.24) 0.40
4.99 (2.29) 5.35 (2.02) 0.03
3.06 (1.54) 3.33 (1.45) 0.02
0.84 (0.46) 0.91 (0.36) 0.03
2.59 (1.83) 2.89 (1.52) 0.02
D are displayed, and represent t tests for normally distributed variables, Wilcoxon
are tests for categorical variables. †The body mass index is the weight in kilograms
100. p values for women with incident ischemic stroke versus those without incident
cardial infarction before age 60 (p  0.32) and apolipoprotein A-I (p  0.15). The
troke were all 0.0005.
DL-C  high-density lipoprotein-cholesterol; IQR  interquartile range; LDL-C ts
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Lipids, CRP, Stroke, and CHD in Women December 5, 2006:2235–42o 0.52; LR chi-square  435.2), although the highly
orrelated variables non–HDL-C (HR 2.93, 95% CI 2.04
o 4.21; LR chi-square  431.1) and apolipoprotein B100
HR 3.25, 95% CI 2.18 to 4.82; LR chi-square  429.7)
lso showed close association with future CHD.
All of the lipid ratios strongly associated with future
HD (Table 3). In contrast to the single lipid measure-
ents, where non-HDL-C and apolipoprotein B100 were
ore closely associated with CHD than TC, the lipid ratio
ith the strongest association was that of TC to HDL-C
HR for highest vs. lowest tertile 4.20, 95% CI 2.79 to 6.32;
R chi-square 457.4). Similarly, the HR for future CHD
or the top versus bottom tertile for the ratio of apolipopro-
ein B100 to HDL-C was 3.98 (95% CI 2.65 to 5.96; LR
hi-square  452.6).
Figures 1 and 2 present the adjusted HRs for each lipid
ariable, hs-CRP, and the lipid ratios for those in the
ighest compared with the lowest tertile. The association
able 2. Adjusted* Hazard Ratios (HRs) of Future Coronary He
ccording to Tertile of Baseline Lipid Levels and High-Sensitivi
Biomarker Tertile 1
holesterol
Total (range, mg/dl) 191.0
Ischemic stroke events 19
HR (95% CI) 1.00
CHD events 52
HR (95% CI) 1.0
LDL (range, mg/dl) 109.9
Ischemic stroke events 29
HR (95% CI) 1.00
CHD events 56
HR (95% CI) 1.0
HDL (range, mg/dl) 44.0
Ischemic stroke events 65
HR (95% CI) 1.00
CHD events 201
HR (95% CI) 1.0
Non-HDL (range, mg/dl) 138.4
Ischemic stroke events 20
HR (95% CI) 1.00
CHD events 38
HR (95% CI) 1.0
polipoprotein
A-I (range, mg/dl) 131.9
Ischemic stroke events 56
HR (95% CI) 1.00
CHD events 170
HR (95% CI) 1.0
B100 (range, mg/dl) 88.9
Ischemic stroke events 21
HR (95% CI) 1.00
CHD events 31
HR (95% CI) 1.0
High-sensitivity CRP (range, mg/l) 0.86
Ischemic stroke events 17
HR (95% CI) 1.00
CHD events 55
HR (95% CI) 1.0
Adjusted for age in years, blood pressure in Framingham categories, body mass ind
CI  confidence interval; HDL  high-density lipoprotein; LDL  low-densityetween each of the lipid variables and ischemic stroke is dimilar in direction of effect to its association with CHD.
isually, the HRs for future CHD for all of the lipid
ariables appear to be slightly stronger than the HR of
uture ischemic stroke for the same lipid, although we
erformed no formal statistical comparison. In contrast, the
R for future ischemic stroke for those in the highest tertile
f hs-CRP appears to be somewhat larger than the HR of
uture CHD, although the 95% CIs overlap (HR 2.76, 95%
I 1.51 to 5.05 for ischemic stroke vs. HR 1.66, 95% CI
.17 to 2.34 for CHD) and no formal statistical comparison
as made.
To clarify whether this apparent difference in the strength
f association between lipid levels and ischemic stroke
ompared with CHD was due to a high proportion of
ardioembolic strokes caused by atrial fibrillation, we re-
eated our analysis after excluding all patients who reported
ither prevalent atrial fibrillation at the time of enrollment
n the WHS or subsequently developed the dysrrhythmia
isease (CHD) and Ischemic Stroke in Initially Healthy Women
Reactive Protein (CRP)
Tertile 2 Tertile 3 ptrend
191.0–224.0 224.0
43 70
1.70 (0.99–2.93) 1.91 (1.13–3.21) 0.02
103 181
1.50 (1.06–2.13) 2.26 (1.64–3.12) 0.0001
109.9–138.5 138.5
36 67
0.87 (0.53–1.44) 1.29 (0.83–2.02) 0.15
102 178
1.44 (1.03–2.02) 2.09 (1.53–2.85) 0.0001
44.0–55.3 55.3
37 30
0.71 (0.47–1.08) 0.57 (0.36–0.92) 0.02
79 56
0.48 (0.36–0.63) 0.38 (0.27–0.52) 0.0001
138.4–173.3 173.3
40 72
1.36 (0.79–2.35) 1.72 (1.03–2.86) 0.03
96 202
1.75 (1.18–2.59) 2.93 (2.04–4.21) 0.0001
131.9–150.2 150.2
36 40
0.59 (0.38–0.91) 0.72 (0.47–1.11) 0.13
102 64
0.62 (0.48–0.80) 0.44 (0.32–0.60) 0.0001
88.9–113.9 113.9
39 72
1.18 (0.69–2.02) 1.47 (0.88–2.44) 0.11
102 203
2.23 (1.47–3.37) 3.25 (2.18–4.82) 0.0001
0.86–2.60 2.60
45 70
2.02 (1.11–3.69) 2.76 (1.51–5.05) 0.003
93 188
1.17 (0.82–1.66) 1.66 (1.17–2.34) 0.001
betes, current smoking status, and randomized treatment assignment.
rotein.art D
ty C-uring the 10 years of follow-up. Of the 132 women who
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December 5, 2006:2235–42 Lipids, CRP, Stroke, and CHD in Womenuffered an ischemic stroke as their first cardiovascular event,
had reported atrial fibrillation upon admission to the study
nd 18 developed atrial fibrillation during the course of
ollow-up, for a total of 109 women with ischemic stroke
ho had no history of atrial fibrillation. The point estimates
or the HRs of future stroke for the third versus first tertile
f each of the lipid values, their ratios, and hs-CRP did not
hange substantially. Specifically, after multivariable adjust-
ent, the HRs of future ischemic stroke for those in the
ighest compared with the lowest tertile were 1.87 (95% CI
.08 to 3.24; ptrend  0.03) for TC, 1.30 (95% CI 0.80 to
.10; ptrend 0.16) for LDL-C, 0.53 (95% CI 0.32 to 0.89;
trend 0.01) for HDL-C, 1.64 (95% CI 0.95 to 2.82, ptrend
0.05) for non–HDL-C, 0.70 (95% CI 0.44 to 1.12; ptrend
0.12) for apolipoprotein A-I, 1.42 (95% CI 0.82 to 2.46;
trend  0.17) for apolipoprotein B100 and 2.65 (95% CI
.39 to 5.08; ptrend 0.007) for hs-CRP. Similarly, those
stimates did not change for the lipid ratios, with the HRs
f future ischemic stroke for the top versus the bottom
ertile equal to 2.24 (95% CI 1.26 to 4.00; ptrend  0.002)
or the TC to HDL-C ratio, 1.81 (95% CI 1.06 to 3.10;
trend  0.02) for the LDL-C to HDL-C ratio, 1.46 (95%
I 0.87 to 2.47; ptrend  0.07) for the ratio of apolipopro-
eins B100 to A-I, and 1.68 (95% CI 0.97 to 2.91; ptrend 
.03) for the ratio of apolipoprotein B100 to HDL-C.
side from the point estimate of the HR for the top versus
ottom tertile of the TC to HDL-C ratio, which changed
rom 1.95 (95% CI 1.16 to 3.26) to 2.24 (95% CI 1.26 to
.00), or approximately 15%, no estimate for any of the HRs
or extreme tertiles changed by more than 7% after we
xcluded women with incident or prevalent atrial fibrillation
able 3. Adjusted* Hazard Ratios (HRs) of Future Coronary He
ccording to Tertile of Various Lipid Ratios at Baseline
Lipid Ratio Tertile 1
otal cholesterol to HDL-C (range) 3.61
Ischemic stroke events 22
HR (95% CI) 1.00
CHD events 28
HR (95% CI) 1.0
DL-C to HDL-C (range) 2.13
Ischemic stroke events 24
HR (95% CI) 1.00
CHD events 30
HR (95% CI) 1.0
po B100 to Apo A-I (range) 0.61
Ischemic stroke events 25
HR (95% CI) 1.00
CHD events 33
HR (95% CI) 1.0
po B100 to HDL-C (range) 1.66
Ischemic stroke events 24
HR (95% CI) 1.00
CHD events 29
HR (95% CI) 1.0
Adjusted for age in years, blood pressure in Framingham categories, body mass ind
CI  confidence interval; HDL-C  high-density lipoprotein-cholesterol; HR art Disease (CHD) and Ischemic Stroke in Initially Healthy Women
Tertile 2 Tertile 3 ptrend
3.61–4.77 4.77
36 74
1.22 (0.70–2.11) 1.95 (1.16–3.26) 0.004
86 222
2.05 (1.32–3.17) 4.20 (2.79–6.32) 0.0001
2.13–2.99 2.99
36 72
1.22 (0.72–2.07) 1.77 (1.08–2.90) 0.01
95 211
2.31 (1.51–3.53) 4.04 (2.71–6.02) 0.0001
0.61–0.82 0.82
37 70
1.00 (0.59–1.68) 1.42 (0.88–2.30) 0.08
88 215
1.74 (1.15–2.62) 3.41 (2.33–4.98) 0.0001
1.66–2.49 2.49
37 71
1.13 (0.66–1.93) 1.62 (0.98–2.68) 0.03
87 220
2.00 (1.30–3.07) 3.98 (2.65–5.96) 0.0001
ex, diabetes, current smoking status, and randomized treatment assignment.
hazard ratio; LDL-C  low-density lipoprotein-cholesterol.rom the analysis.
A
ligure 1. Adjusted hazard ratios (HR) and 95% confidence intervals (CI)
or future ischemic stroke (open circles) and coronary heart disease (closed
ircles) among those in extreme tertiles of each lipid variable and
igh-sensitivity C-reactive protein (Hs-CRP). Hazard ratios are adjusted
or age (years), blood pressure (Framingham categories), diabetes, current
moking status, body mass index, and randomized treatment assignment.
or ease of comparison, we have used the highest tertile as the referent for
igh-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo)
-I. Apo B100  apolipoprotein B100; LDL-C  low-density
ipoprotein-cholesterol; Tot Chol  total cholesterol.
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nd we found no significant linear relationship between
emorrhagic stroke and any of the lipid variables or hs-
RP, using both minimally adjusted (for age and random-
zed treatment assignment) and fully adjusted proportional
azards models.
Finally, because there is evidence in the literature that
xercise (29) and alcohol consumption (30) may be related
o stroke risk, and both are known to be related to
holesterol (and in particular HDL-C) levels (31,32), we
onstructed a Cox model which included exercise (exercise
ess than 1 time per week, 1 to 3 times per week, and at least
times per week) and alcohol consumption (less than 3
rinks per month, 1 to 6 drinks per week, and at least 1
rink per day) in addition to the other variables included in
ur fully adjusted model. None of the HRs for extreme
ertiles of any of the lipid values or hs-CRP changed by
ore than 5% with the addition of alcohol and exercise to
he previously constructed model.
ISCUSSION
n this prospective cohort of initially healthy women, we
irectly compared standard lipid measures, apolipoproteins
100 and A-I, and hs-CRP as risk determinants for future
schemic stroke compared with CHD. Overall, we found
hat lipid levels are significantly associated with a risk of
uture ischemic stroke in a direction similar to that of CHD.
owever, for all lipid measures, the magnitude of effect
ppeared smaller for future ischemic stroke than for CHD.
lthough hs-CRP was a significant predictor of both
linical events, the magnitude of effect, if anything, was
omewhat greater for ischemic stroke than for CHD. We
igure 2. Adjusted hazard ratios and 95% confidence intervals for future
schemic stroke (open circles) and coronary heart disease (closed circles)
mong those in extreme tertiles of each lipid ratio. Hazard ratios are
djusted for age (years), blood pressure (Framingham categories), diabetes,
urrent smoking status, body mass index, and randomized treatment
ssignment. Abbreviations as in Figure 1.ould demonstrate no linear relationship between future temorrhagic stroke and lipid or hs-CRP levels. No substan-
ive differences were observed after exclusion of those with
revalent or incident atrial fibrillation.
We believe these data are clinically relevant for several
easons. First, a clear link between lipids and future stroke
as not been established. In our population of initially
ealthy U.S. women, non–HDL-C and HDL-C were
ssociated with future ischemic stroke risk in a way that was
learly dose-dependent, whereas TC was also associated
ith future ischemic stroke in a somewhat weaker dose-
ependent manner. There was a trend toward an increased
isk of ischemic stroke with increasing tertiles of apoli-
oproteins B100 and A-I and LDL-C, although the trend
as not significant. All the lipid ratios except that of
polipoproteins B100 to A-I showed a consistently increas-
ng risk of stroke with increasing levels of the ratio.
As anticipated, lipid levels were all clearly associated with
he risks of incident CHD. In all cases but 1 (the ratio of
polipoproteins B100 to A-I), the direction and magnitude
f the association between the measured lipid variables and
he end points of ischemic stroke and CHD were not
ignificantly different. Although ischemic stroke represents
heterogenous disorder (33), these data provide evidence
hat in this population hyperlipidemia confers a risk of both
schemic heart disease and ischemic cerebrovascular disease.
Previous literature has noted the lack of association
etween lipids and ischemic stroke. Some studies have been
nable to differentiate between hemorrhagic and ischemic
troke, and have suggested that cholesterol’s positive asso-
iation with ischemic stroke may be concealed by a negative
elationship with hemorrhagic stroke (11). Although a
elationship between lipids and ischemic and hemorrhagic
troke was suggested by evidence from MRFIT (Multiple
isk Factor Intervention Trial) (34), we could not demon-
trate a linear relationship between the risk of hemorrhagic
troke and lipid levels. We are significantly limited, how-
ver, by the number of hemorrhagic strokes (n  31) in our
opulation. Other early research reports may have been
imited by sample size (9,10), by combining fatal and
ncident ischemic stroke (35), or by examining only fatal
troke (12).
More recently, researchers working on a number of well
haracterized cohorts, such as the ARIC (Atherosclerosis
isk in Communities) study (14) and the Physician’s Health
tudy (15), have reported similarly negative results. In the
RIC cohort, Shahar et al. (14) reported a total of 305
schemic strokes, 144 of which were in women. Although
hey do not report the risk associated with elevated levels of
C, non–HDL-C, or the TC to HDL-C ratio, which were
he lipid measures that demonstrated the strongest associ-
tion with future ischemic stroke in our cohort, the HRs of
schemic stroke among women for the highest versus the
owest quartile of LDL-C (HR 1.33, 95% CI 0.81 to 2.20),
polipoprotein B100 (HR 1.61, 95% CI 0.96 to 2.69), and
DL-C (HR 0.68, 95% CI 0.36 to 1.27) are quite similaro the HRs for extreme tertiles of those lipid measures that
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December 5, 2006:2235–42 Lipids, CRP, Stroke, and CHD in Womene report here. An alternative explanation is that the
opulation of women included in the WHS has fewer
stablished risk factors for ischemic stroke than that re-
ruited for the ARIC study, so that elevated lipid levels play
more central role in the pathophysiology of ischemic
troke among the WHS women.
Although Bowman et al. (15) were unable to show a
elationship between cholesterol levels and ischemic stroke
n a nested case-control study of 296 ischemic strokes from
he Physician’s Health Study, other studies performed
xclusively in men have demonstrated a positive association
etween lipids and ischemic stroke (34–37). Investigators
orking with a cohort of subjects enrolled in a health
aintenance organization found an odds ratio (OR) of
schemic stroke of 1.6 (95% CI 1.3 to 2.0) for the highest
ersus the lowest quintile of TC and a protective effect of
he highest levels of HDL-C (OR 0.8, 95% CI 0.6 to 1.0 for
xtreme quintiles) (33), results that are consistent with
ecently published findings from Korea (38). Sacco et al.
39), using an ethnically diverse community-based cohort in
ew York City, also demonstrated a protective effect of
igh HDL-C levels on the risk of ischemic stroke.
The association we report between hs-CRP and future
schemic stroke has been demonstrated previously in both
en (2) and cohorts composed of men and women (16,17).
e were able to confirm that relationship in our population
f women and to demonstrate that the relationship between
s-CRP and future ischemic stroke (HR 2.76, 95% CI 1.51
o 5.05; LR chi-square  213.7) was at least as strong as
hat of the strongest lipid risk determinant, the ratio of TC
o HDL-C (HR 1.95, 95% CI 1.16 to 3.26; LR chi-square
210.1). Whereas the lipid values were highly correlated
ith one another, the correlations between hs-CRP and the
ipid parameters were weaker (range 0.15 to 0.33) (28).
his observation is consistent with the hypothesis that both
nflammation and hyperlipidemia contribute to the devel-
pment of ischemic stroke and is consistent with earlier data
hat markers of inflammation, such as fibrinogen (18) and
he leukocyte count (19), are related to incident stroke.
Another possibility is that whereas most ischemic stroke
s the result of atherosclerotic processes, cardioembolic
troke (e.g., thromboembolism from atrial fibrillation) may
ot be closely associated with hyperlipidemia. Although
s-CRP is a well established marker of the systemic inflam-
ation intrinsic to atherosclerosis in this cohort (5) and
thers (2,6–8), elevated levels of hs-CRP have also been
ssociated with the presence of chronic and paroxysmal
trial fibrillation (40) and may predict incident atrial fibril-
ation (41). By capturing subjects who are predisposed to
oth etiologies of ischemic stroke, hs-CRP may serve as a
ore potent marker of future ischemic stroke than lipids
lone. However, our findings that excluding subjects with
trial fibrillation does not substantially alter the point
stimates of the hazard ratios for any of the lipids, their
atios, or hs-CRP does not support this hypothesis.The reliability of our laboratory assays and the large scale
nd prospective nature of the present cohort serve to reduce
he possibility of laboratory error, bias, or chance as expla-
ations for our findings. We elected to exclude women who
ere using hormone therapy at the time of lipid analysis.
lthough doing so may limit the generalizability of our
esults somewhat, we did so on an a priori basis because of
uidelines issued by the U.S. Preventive Task Force (24)
nd because of evidence in the literature that hormone use
lters both lipid levels (25,26) and hs-CRP levels (27) and is
ssociated with socioeconomic status, education, exercise,
nd other unmeasured confounders of CHD and ischemic
troke events (42,43). Because hormone therapy use is
eclining (44,45), we believe that our results are applicable
o a large segment of the U.S. population. Our study
ncluded only middle-aged women participating in a ran-
omized controlled trial who are more likely to be healthy
han their peers. We measured lipid and inflammatory
iomarkers once, and simple intraindividual variability may
ave altered circulating lipid levels and caused us to mis-
lassify the exposure. However, the overall relationship
etween lipids and cardiovascular disease in the present
tudy (28) is similar to that in other studies conducted
redominantly in men (4). In addition, statin use was very
ow at the time of lipid analysis in the WHS (20), and the
nitiation of statins among women with high lipid levels
ould tend to bias our results toward the null hypothesis.
Our analysis supports the use of standard lipid measures
uch as TC, HDL-C, non–HDL-C, the ratio of TC to
DL-C, and hs-CRP in the assessment of risk for ischemic
troke in addition to CHD. Although the risk of CHD for
given level of lipid may be somewhat higher than the risk
f ischemic stroke, the risks are quite similar in direction.
nflammation, as measured by hs-CRP, and hyperlipidemia
ppear to play a key role in the development of cerebrovas-
ular atherosclerosis and ischemic stroke, consistent with
heir well-known role in the pathophysiology of coronary
therosclerosis and CHD.
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